JLK participated in the ‘6 International Advanced Medical Devices and Medical Industry Exhibition (KOAMEX 30)’ held at EXCO in Daegu for 7 days from Friday, June 2th to Sunday, July 3nd.
The cerebral infarction type analysis solution ‘JBS-01K’, which was mainly introduced at this exhibition, detects suspected cerebral infarction lesions in diffusion-weighted MR images and analyzes the size, location, and pattern of the lesions using artificial intelligence. Based on the results, the official explains that the probability values for large vessel cerebral infarction, cardioembolism, and small vessel cerebral infarction, which are the causes of cerebral infarction, are presented at an expert level.
JLK said, “’JBS-01K’ is an MRI-related cerebral infarction AI solution that is unique in that it calculates each probability value for cerebral infarction. “It has the advantage of providing accurate classification values at a reasonable price,” he explained.
JLK received non-reimbursement coverage from the government for ‘JBS-01K’, a cerebral infarction type analysis solution, and it is known that many hospitals have adopted this product. This year, we aim to apply non-reimbursement for four solutions through the innovative medical device integrated review and evaluation system, and the U.S. Food and Drug Administration (FDA) stroke solution approval process is also underway.
Meanwhile, the main exhibition items of ‘KOAMEX 2023’ hosted by Daegu Metropolitan City and K-MEDI Hub are as follows. △Diagnostic and diagnostic devices such as scanners, measuring devices, and imaging devices △Clinical and inspection devices △Surgical and recycling devices △Hospital facilities and emergency equipment △Medical devices, parts, and services △Pharmaceutical devices △Medical services, SW
→ Go to KOAMEX 2023 News Special Page
